TrialModern rheumatology2014

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.

Yoshiya Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.